CRO Sector Q2 2023 Update – Industry-wide Developments & Competitive Differentiation

  • Private Equity
  • Healthcare
  • North America


Former Director at Cytel Inc


  • Significant trends and developments within a capital-constrained CRO (contract research organisation) market, delineating the major competitors in the space, including Iqvia (NYSE: IQV), Icon (NASDAQ: ICLR), PPD, Medpace (NASDAQ: MEDP) and Syneos (NASDAQ: SYNH)
  • Overall market growth assessment breaking down key criteria – book-to-bills, product expansion, market shares and price wars
  • Pre-clinical and clinical research capabilities and associated funding environments, differentiating on the basis of competency and required assets
  • Consolidation and divestiture activity, especially following Labcorp’s (NYSE: LH) divestiture of Covance, discussing areas of potential M&A – pharmacovigilance, health economics, clinical trial design and tech solutions
  • 6-12-month market outlook, outlining near-term headwinds/tailwinds, R&D growth opportunities and therapeutic clinical advancements


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited